Jounce therapeutics, inc. (JNCE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Revenue:
License and collaboration revenue—related party

0

0

119,445

17,446

10,981

20,100

14,528

19,378

11,195

12,989

18,077

20,289

20,289

20,289

16,908

0

0

Operating expenses:
Research and development

19,646

16,610

15,115

18,130

17,280

16,644

16,751

18,495

18,162

18,557

17,094

17,188

14,959

10,654

9,505

6,490

8,255

General and administrative

7,539

6,922

6,483

7,323

7,192

6,601

6,517

6,523

6,802

5,984

5,371

6,129

5,577

4,653

3,588

5,872

2,646

Total operating expenses

27,185

23,532

21,598

25,453

24,472

23,245

23,268

25,018

24,964

24,541

22,465

23,317

20,536

15,307

13,093

12,362

10,901

Operating loss

-27,185

-23,532

97,847

-8,007

-13,491

-3,145

-8,740

-5,640

-13,769

-11,552

-4,388

-3,028

-247

4,982

3,815

-12,362

-10,901

Other income, net

750

875

1,025

1,026

1,126

1,151

1,103

966

741

703

721

752

632

484

255

13

11

Total other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

484

255

13

11

Loss before provision for income taxes

-26,435

-22,657

98,872

-6,981

-12,365

-1,994

-7,637

-4,674

-13,028

-

-3,667

-2,276

-

-

4,070

-12,349

-

Provision for income taxes

8

10

12

12

12

46

0

0

0

-

417

1,104

-

-

0

0

-

Net Income (Loss) Attributable to Parent

-26,443

-22,667

98,860

-6,993

-12,377

-2,040

-7,637

-4,674

-13,028

-9,364

-4,084

-3,380

385

5,466

4,070

-12,349

-10,890

Net income attributable to preferred stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,385

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-9,364

-4,084

-3,380

-409

4,050

139

-14,393

-12,934

Net income (loss) per share, basic (in dollars per share)

-

-

2.99

-

-

-

-0.23

-

-

-

-

-

-

-

0.07

-

-

Net income (loss) per share, diluted (in dollars per share)

-

-

2.90

-

-

-

-0.23

-

-

-

-

-

-

-

0.03

-

-

Net loss per share, basic and diluted (in dollars per share)

-0.78

-

-

-0.21

-0.38

-

-

-0.14

-0.40

-0.31

-0.13

-0.11

-0.02

-

-

-7.23

-6.81

Weighted-average common shares outstanding, basic (in shares)

-

-

33,112

-

-

-

32,641

-

-

-

-

-

-

-

2,131

-

-

Weighted-average common shares outstanding, diluted (in shares)

-

-

34,141

-

-

-

32,641

-

-

-

-

-

-

-

4,751

-

-

Weighted-average common shares outstanding, basic and diluted (in shares)

34,029

-

-

32,973

32,959

-

-

32,497

32,373

32,351

32,182

32,144

23,543

-

-

1,991

1,899

Comprehensive loss:
Comprehensive income (loss):
Net Income (Loss) Attributable to Parent

-26,443

-22,667

98,860

-6,993

-12,377

-2,040

-7,637

-4,674

-13,028

-9,364

-4,084

-3,380

385

5,466

4,070

-12,349

-10,890

Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent

90

-24

-57

84

129

62

76

135

58

-

-

-

-

-

-

-

-

Comprehensive loss

-26,353

-22,691

98,803

-6,909

-12,248

-1,978

-7,561

-4,539

-12,970

-

-

-

-

-

-

-

-